Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-3373 versus adalimumab in moderate to severe rheumatoid arthritis on methotrexate
NL-OMON48179Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ABBV-3373, adalimumab and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Change in DAS28(CRP) from baseline at Week 12. Started Sep 2019; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON48179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48179.